DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO
Application 2588/KOLNP/2005 published 2006-11-24, filed 2005-12-13
The present invention relates to certain pyrazole derivatives of Formula (I) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A-serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the prophylaxis or treatment of platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, reducing the risk of blood clot formation, asthma or symptoms thereof, agitation or a symptom, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders and the like. The present invention also relates to the method of prophylaxis or treatment of 5-HT2A-serotonin receptor mediated disorders in combination with a dopamine D2 receptor antagonist such as haloperidol, administered separately or together. (FIG. - Nil)
Applicant
ARENA PHARMACEUTICALS INC
6166 NANCY RIDGE DRIVE SAN DIEGO CA 92121 USA
Inventor
1. TEEGARDEN BRADLEY 2. JAYAKUMAR HONNAPPA 3. LI HIONGMEI 4. STRAH-PLEYNET SONJA 5. DOSA PETER IAN
International Info
Classification: C07D 231/16,A61K 31/415
Publication Number: WO 04/012254 A1
Application Date: 2004-07-21
Priority Information
60/489,572 US 2003-07-22